Thermo Fisher strengthens antibody services through Affymetrix merger

By Dan Stanton contact

- Last updated on GMT

Image: iStock
Image: iStock

Related tags: Biology, Dna

Thermo Fisher has expanded its life sciences tools business through the acquisition of biological analysis firm Affymetrix for $1.3bn.

The deal was originally announced in January​ but two weeks ago​ Affymetrix received a rival offer of $1.5bn from Origin Technologies Corporation.

This was rejected on the grounds that the deal was backed by an insufficient financial package, and yesterday the firms announced the acquisition has now been completed, with Affymetrix becoming a wholly-owned subsidiary of Thermo Fisher.

“This is a great outcome for both companies,”​ said Thermo Fisher CEO Marc Casper in a statement. “With Affymetrix, we now have an expanded antibody portfolio to strengthen our leadership in biosciences, as well as new genetic analysis capabilities to better serve clinical and applied markets.”

He added the integration of Affymetrix has been ongoing since the deal was announced in January. “[It is] progressing well and we look forward to creating value through the strategic and financial benefits of the transaction.”

Thermo M&A

The acquisition is the latest for Thermo Fisher as it strengthens its bioprocessing and life sciences businesses.

In 2014​, the firm bought Life Technologies for $13.6bn, adding sera and media, chromatography instruments and purification consumables to its portfolio, as well as the DNA sequencing Ion Torrent technology platform.

And last year​, the firm bolstered its single-use bioprocessing technologies offering through the acquisition of ASI.

Furthermore, the company was rumoured to have made a bid for Pall Corporation​, the filtration and separation firm which was snapped up for $14bn in September​ by Danaher.

Related news

Show more

Related products

Microsampling in Early Phase Drug Development

Microsampling in Early Phase Drug Development

Altasciences | 10-May-2022 | Technical / White Paper

Microsampling significantly lessens the volume of blood and plasma/serum that is collected and analyzed to determine circulating concentrations of therapeutic...

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Partner with Experts in Precision Medicine

Partner with Experts in Precision Medicine

CellCarta | 17-Jan-2022 | Product Brochure

At CellCarta, we’re dedicated to working with our partners to further the limitless potential of precision medicine. Our broad technology offering is designed...

Related suppliers